{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:39Z","timestamp":1794047559948,"version":"4.8.0"},"reference-count":0,"publisher":"Ferrata Storti Foundation (Haematologica)","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Pediatric refractory\/relapsed acute myeloid leukemia (r\/r-AML), myelodysplastic syndromes with excess blasts (MDSEB), and therapy-related MDS\/AML (t-MDS\/AML) remain a clinical challenge due to high rate of treatment failure. Venetoclax plus azacytidine (ven\/aza) has transformed adult myeloid neoplasm treatment, but pediatric data are limited and heterogeneous.\nThis AIEOP retrospective, multicenter study analyzed 50 patients (M\/F=1.8\/1; median age 11 years) with r\/r-AML (n=32), MDS-EB (n=10), or t-MDS\/AML (n=8) treated with ven\/aza. Responses were defined as complete (CR), partial (PR), or non-response (NR) based on bone marrow (BM) blast evaluation. Adverse events (AEs) were graded per CTCAE v5.0; outcomes were evaluated with Kaplan-Meier and Cox-regression analysis.\nPatients received a median of 2 cycles (range, 1-7). Grade \u22653 AEs occurred in 34% of patients. Overall, 30 patients (60%) achieved CR (24 MRD-negative), 9 (18%) PR, and 11 (22%) NR. CR were 58%, 57% and 100% in KMT2A-AML, FLT3-ITD-AML (ven\/aza+FLT3-inhibitors) and UBTF-TD myeloid neoplasms, respectively. In 10 MDS-EB, 7 CR and 2 PR were recorded. In 8 t-MDS\/AML, we observed 5 CR and 2 PR. Thirty-three patients (66%) underwent hematopoietic cell transplantation (HCT), after a median of 97 days (range: 33-933) from ven\/aza start. Median follow-up was 389 days (range 36-1405). Two-year event-free survival (EFS) was 54.5% (CI:46.7-62.3), being 75.8% in transplanted patients, and 77.2% in those achieving CR. CR and HCT were associated with better EFS. Ven\/aza shows substantial activity and manageable toxicity in pediatric high-risk myeloid diseases, especially as a bridge to HCT and in specific molecular subgroups, supporting future, prospective, genetically-guided studies.<\/jats:p>","DOI":"10.3324\/haematol.2026.300775","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T07:22:37Z","timestamp":1779348157000},"source":"Crossref","is-referenced-by-count":1,"title":["Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory\/relapsed acute myeloid leukemia and therapy-related myeloid neoplasms"],"prefix":"10.3324","author":[{"given":"Francesco","family":"Baccelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Merli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Pigazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Buldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Becilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Paganelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Leardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Muratore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Vendemini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Beneduce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Tumino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sieni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mastrodicasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Maffeis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Paolo","family":"Tambaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Masetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2026,5,21]]},"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/14190\/80300","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/14190\/80300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:14:16Z","timestamp":1794046456000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/14190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":0,"URL":"https:\/\/doi.org\/10.3324\/haematol.2026.300775","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,21]]}}}